11:15 AM EDT, 06/26/2024 (MT Newswires) -- Repare Therapeutics ( RPTX ) said Wednesday that initial data from a phase one study of lunresertib, or RP-6306, combined with Folfiri showed "promising" efficacy and tolerability in patients with advanced solid tumors.

The data helped identify the preliminary recommended phase 2 dose of 60 milligrams lunresertib twice a day with standard Folfiri, the company said.

Repare said the combination therapy was well tolerated and did not result in excess toxicity above expected rates.

Repare shares were 2.5% down in recent trading.

Price: 3.33, Change: -0.09, Percent Change: -2.49